Histopathology Large with IHC at Lahore PCR Lab

Histopathology Large with IHC at Lahore PCR Lab

Histopathology is the definitive gold standard for diagnosing complex diseases, particularly solid tumors and inflammatory conditions. When a large tissue specimen—such as a radical mastectomy, hemicolectomy, major organ resection, or large diagnostic biopsy—is submitted to Lahore PCR Lab, it undergoes a meticulous diagnostic pathway. Standard histopathology relies on Hematoxylin and Eosin (H&E) staining to visualize cellular morphology under a light microscope. While H&E staining is essential, it is sometimes insufficient to determine the exact cellular lineage, primary origin, or molecular characteristics of a tumor. This is where Immunohistochemistry (IHC) becomes indispensable.

Immunohistochemistry utilizes the high specificity of antigen-antibody reactions to identify specific proteins (antigens) within tissue sections. By applying a targeted panel of monoclonal or polyclonal antibodies, pathologists at Lahore PCR Lab can visualize the expression of cellular markers. This dual approach—combining macroscopic and microscopic morphology with immunophenotypic profiling—provides an unparalleled level of diagnostic accuracy. It is critical for tumor staging, prognostic assessment, and formulating personalized therapeutic strategies, such as targeted immunotherapy or chemotherapy. The clinical importance of this combined test lies in its ability to transform a general diagnosis into a precise, actionable molecular profile, ensuring that patients in Lahore and across Pakistan receive the most effective, evidence-based treatment plans.

Clinical Procedure: What to Expect

Patient Preparation

Because a Histopathology Large with IHC test is performed on tissue specimens that have already been surgically excised, there is no direct physical preparation required of the patient at the laboratory itself. However, critical pre-analytical preparation must be managed by the surgical and clinical team to ensure specimen integrity:

• Immediate Fixation: The excised tissue must be placed immediately into a container filled with 10% neutral buffered formalin. The volume of formalin should ideally be at least 10 times the volume of the tissue specimen to ensure adequate penetration and prevent autolysis.
• Minimize Cold Ischemia Time: The time interval between tissue resection and formalin fixation (cold ischemia time) must be kept under one hour. Prolonged cold ischemia can degrade labile proteins and lead to false-negative IHC results, especially for hormone receptors like ER/PR.
• Clinical History Provision: It is vital to provide a complete clinical history, including previous biopsy reports, radiological findings, and the specific anatomical site of the specimen. This information guides the pathologist in selecting the most relevant IHC antibody panel.
• Avoid Freezing or Drying: The tissue specimen must never be frozen, allowed to dry out, or exposed to unbuffered formalin, as these actions destroy cellular architecture and mask key antigenic epitopes.

During the Procedure

Once the large specimen is received at Lahore PCR Lab, it undergoes a highly standardized, multi-step laboratory process carried out by trained histotechnologists and evaluated by consultant pathologists:

• Gross Examination: A consultant pathologist performs a detailed macroscopic evaluation. The specimen is weighed, measured, and described. The pathologist carefully examines surgical margins and slices the tissue to select representative areas for microscopic analysis.
• Tissue Processing and Embedding: The selected tissue pieces are placed in cassettes and processed using an automated tissue processor. This involves dehydration through graded alcohols, clearing in xylene, and infiltration with molten paraffin wax. The tissue is then embedded into solid paraffin blocks (FFPE).
• Microtomy: Extremely thin sections (3 to 5 microns thick) are cut from the paraffin blocks using a high-precision microtome. These sections are floated onto water baths and mounted onto specialized, positively charged glass slides designed to retain tissue during IHC processing.
• Antigen Retrieval: To expose proteins that may have been masked during formalin fixation, the slides undergo heat-induced epitope retrieval (HIER) or enzymatic digestion.
• Antibody Incubation and Detection: The slides are incubated with primary antibodies specific to the target proteins. After washing, secondary antibodies conjugated with enzymes (such as horseradish peroxidase) are applied. A chromogen substrate (like diaminobenzidine) is added, which reacts to produce a visible brown precipitate at the site of antigen expression.
• Microscopic Evaluation: The slides are counterstained, coverslipped, and meticulously analyzed under a high-resolution light microscope by a specialist pathologist to correlate morphology with IHC staining patterns.

When is a Histopathology Large with IHC Performed?

Characterization of Complex Epithelial and Non-Epithelial Malignancies

Physicians request a histopathology large with IHC test when a patient undergoes a major surgical resection for a suspected or confirmed tumor. While standard H&E staining reveals the general architecture of the tumor, IHC is required to differentiate between poorly differentiated carcinomas, sarcomas, melanomas, and lymphomas. For instance, if a large retroperitoneal mass is resected, the morphology may appear highly pleomorphic and non-specific. By applying a targeted panel of IHC markers (such as cytokeratins, vimentin, S100, and LCA), the pathologist can definitively classify the tumor’s histogenesis, allowing the clinical team to initiate the correct treatment protocol.

Identification of the Primary Site in Metastatic Tumors

In cases where a patient presents with metastatic disease without an obvious primary source—known as Cancer of Unknown Primary (CUP)—a biopsy or resection of the metastatic lesion (e.g., a large lymph node or liver mass) is subjected to IHC. Pathologists utilize specific lineage-associated transcription factors and cytokeratin profiles (such as CK7, CK20, TTF-1, CDX2, and PAX8) to trace the cellular origin of the metastasis. Identifying whether a metastatic adenocarcinoma originated in the lung, colon, breast, or ovary is vital, as systemic therapies are highly specific to the primary site of origin.

Determination of Prognostic and Predictive Biomarkers in Breast and Prostate Cancers

For large breast resections (mastectomies or lumpectomies), histopathology with IHC is standard of care. IHC is used to evaluate the expression of Estrogen Receptors (ER), Progesterone Receptors (PR), and Human Epidermal Growth Factor Receptor 2 (HER2/neu), alongside the Ki-67 proliferation index. These markers are predictive of response to endocrine therapies (like tamoxifen or aromatase inhibitors) and targeted monoclonal antibodies (like trastuzumab). Similarly, in prostate resections, IHC markers like AMACR and p63 help confirm malignancy and assess tumor aggressiveness, directly influencing post-operative management.

Subtyping of Lymphoproliferative Disorders and Lymphomas

When a large lymph node biopsy or splenectomy specimen is submitted, diagnosing lymphoma requires a comprehensive IHC panel. Lymphomas are highly diverse malignancies of the immune system that cannot be accurately classified by morphology alone. Pathologists use IHC to determine whether the neoplastic cells are of B-cell lineage (expressing CD20, CD19), T-cell lineage (expressing CD3, CD5), or Hodgkin lymphoma (expressing CD30, CD15). Accurate subtyping is critical because the prognosis and therapeutic regimens for Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma differ drastically.

Evaluation of Therapeutic Response and Post-Neoadjuvant Staging

Patients who receive neoadjuvant chemotherapy or radiotherapy prior to surgical resection of a large tumor require detailed histopathological assessment of the resected specimen to evaluate treatment response. Pathologists assess the percentage of residual viable tumor versus therapy-induced necrosis and fibrosis. IHC is often employed in these post-treatment specimens to detect microscopic clusters of viable tumor cells that may be obscured by extensive inflammatory infiltrates or reactive stromal changes, ensuring highly accurate pathological staging (ypTNM).

What Does a Histopathology Large with IHC Detect?

This advanced diagnostic test is capable of detecting and characterizing a wide array of pathological findings, including:

• Presence of invasive epithelial malignancy (carcinoma)
• Identification of mesenchymal differentiation (sarcoma)
• Differentiation between Hodgkin and Non-Hodgkin lymphoma
• Determination of tumor histological grade (well, moderately, or poorly differentiated)
• Evaluation of proximal, distal, and radial surgical resection margins
• Detection of lymphovascular invasion (LVI) indicating metastatic potential
• Presence of perineural invasion (PNI) suggesting local aggressive behavior
• Metastatic involvement of regional lymph nodes (including macrometastases and micrometastases)
• Estrogen Receptor (ER) positivity or negativity in breast carcinoma
• Progesterone Receptor (PR) expression levels
• HER2/neu protein overexpression (Score 0, 1+, 2+, or 3+)
• Ki-67 proliferation index to determine cellular growth fraction
• Lineage determination using Cytokeratin 7 (CK7) and Cytokeratin 20 (CK20)
• Identification of lung primary origin via Thyroid Transcription Factor-1 (TTF-1) expression
• Confirmation of colorectal origin using CDX2 positivity
• Detection of neuroendocrine differentiation using Synaptophysin and Chromogranin A
• Identification of melanocytic lineage using S100, Melan-A, and HMB-45
• Evaluation of prostate-specific markers like PSA and AMACR (Alpha-Methylacyl-CoA Racemase)
• Assessment of myoepithelial cell layer integrity using p63 or Calponin to distinguish in situ from invasive carcinoma
• Detection of mismatch repair (MMR) protein deficiency (MLH1, MSH2, MSH6, PMS2) for Lynch syndrome screening
• Identification of vascular tumors using CD31 and CD34 markers
• Differentiation of mesothelioma from adenocarcinoma using Calretinin and WT1
• Detection of GIST (Gastrointestinal Stromal Tumor) using CD117 (c-KIT) and DOG1
• Identification of anaplastic large cell lymphoma using ALK-1 protein expression
• Assessment of tumor-infiltrating lymphocytes and PD-L1 expression for immunotherapy eligibility

Turnaround Time and Report Access at Lahore PCR Lab

Because of the complex and highly detailed nature of processing large surgical specimens—which require thorough fixation, detailed grossing, overnight tissue processing, slide cutting, H&E staining, and subsequent automated IHC runs that take several hours per panel—the turnaround time for a Histopathology Large with IHC at Lahore PCR Lab typically ranges from 5 to 7 working days. This timeline ensures that every step of the diagnostic pathway is subjected to rigorous quality control and peer review by senior pathologists. Patients and referring physicians can access reports securely online via the Lahore PCR Lab web portal, receive SMS alerts upon report completion, or collect physical copies directly from the laboratory.

Histopathology Large with IHC Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Tissue Architecture	Normal, organized cellular layers and intact basement membranes	Disrupted architecture, stromal invasion, solid sheets, or glandular crowding
Nuclear Morphology	Uniform, small nuclei with smooth nuclear membranes	Pleomorphism, hyperchromasia, prominent nucleoli, atypical mitotic figures
Surgical Margins	Negative for tumor cells (clear margins)	Involved margins (tumor cells present at the inked resection edge)
Lymphovascular Space	No tumor cells within endothelial-lined channels	Lymphovascular invasion (LVI present), indicating elevated risk of metastasis
Lymph Nodes	Reactive follicular hyperplasia or normal lymphoid architecture	Metastatic tumor deposits, effacement of architecture by lymphoma cells
Hormone Receptors (ER/PR)	Typically negative in non-target normal tissues	Positive expression in breast carcinoma (predictive of hormone therapy response)
HER2/neu Expression	Negative or low expression (Score 0 or 1+)	Overexpressed (Score 3+), indicating eligibility for anti-HER2 targeted therapy
Proliferation Index (Ki-67)	Low proliferative activity (typically < 5% in normal tissues)	Elevated Ki-67 index (e.g., > 30%), indicating highly proliferative, aggressive tumor

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for Histopathology Large with IHC?

• Experienced Healthcare Professionals: Our team consists of highly qualified, board-certified histopathologists with extensive experience in surgical pathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient well-being by ensuring meticulous handling of every specimen to deliver the most accurate diagnostic answers.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international laboratory standards and quality control protocols for all staining and IHC procedures.
• Professional Reporting: Reports are detailed, comprehensive, and structured according to international cancer reporting guidelines (CAP protocols).
• Modern Diagnostic Approach: We utilize advanced automated IHC platforms that minimize manual errors and ensure highly reproducible staining results.
• Comfortable Environment: Our sample collection centers are designed to provide a professional, clean, and welcoming experience for patients submitting specimens.
• Convenient Location: Located centrally in Lahore, our main lab and collection points are easily accessible for patients and hospitals across the city.
• Commitment to Accurate Diagnosis: We understand that a pathology report guides critical cancer treatment, and we are committed to absolute diagnostic precision.